[The expression of cortactin in colorectal cancer and its relationship with clinicopathological and prognostic parameters].

Objective: To investigate the expression of cortactin in colorectal cancer and its correlation with clinicopathological parameters and prognosis. Methods: The expressions of cortactin in normal colorectal mucosal tissue and colorectal cancer tissue in paraffin-embedded tissue microarray from 319 patients who were diagnosed as colorectal cancer and treated in Cancer Hospital of Chinese Academy of Medical Sciences from 2006 to 2009 was detected by immunohistochemistry. Kaplan-Meier method and Log rank test were used for survival analysis, and Cox proportional risk regression model was used for multivariate analysis. Results: The positive expression rates of cortactin in colorectal cancer tissue and normal colorectal mucosal tissue were 61.1% (195/319) and 5.6% (18/319, P<0.001), respectively. T-stage, N-stage, American Joint Committee on Cancer (AJCC) stage, degree of tumor differentiation, neural invasion and preoperative carcinoembryonic antigen (CEA) levels were associated with the expression of cortactin (P<0.05). The positive expression of cortactin was associated with poorer disease-free survival (P=0.036) and overall survival (P=0.043), and the effect was more significant in patients with stage Ⅱ to Ⅲ. For patients with stage Ⅱ-Ⅲ colorectal cancer, postoperative adjuvant therapy was associated with disease-free survival (P=0.007) and overall survival (P=0.015). The vascular tumor embolus, pathological type, preoperative CEA level and cortactin expression were independent influencing factors for disease-free survival (P<0.05). The age, AJCC stage, preoperative CEA level and cortactin expression were independent influencing factors for overall survival (P<0.05). Preoperative CEA level and cortactin expression were independent influencing factors for disease-free survival and overall survival (P<0.05). Conclusion: Cortactin is expressed in colorectal cancer and in stage Ⅱ-Ⅲ patients, it is a potential predictor of colorectal cancer prognosis.

[Clinical application of fusion indocyanine green fluorescence imaging in total laparoscopic radical resection for right colon cancer].

Objective: This study aims to explore the clinical value of fusion indocyanine green fluorescence imaging (FIGFI) in total laparoscopic radical resection for right colon cancer. Methods: From October, 2018 to December, 2018, 15 patients who underwent total laparoscopic radical resection for right colon cancer using FIGFI in Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College were retrospectively enrolled in this study. Data regarding surgical outcomes, postoperative recovery, pathological outcomes and complications were collected and analyzed. Results: All patients successfully underwent total laparoscopic radical resection for right colon cancer using FIGFI. 1 patients (6.7%) received extended resection of bowel due to poor blood supply after mesentery excision. The average operation time was 133.7 minutes and intraoperative blood loss was 26.7 ml. The average time to ground activities, fluid diet intake, first flatus and postoperative hospitalization were 19.1 h, 11.7 h, 32.5 h and 5.0 d, respectively. The average length of tumor was 4.5 cm. The average proximal and distal resection margins were 14.9 cm and 12.1 cm, respectively. The average number of lymph nodes retrieved was 29.3 per patient. Only one patient suffered from incisional fat liquefaction after surgery and was managed effectively by regular dressing change. No severe complications such as indocyanine green allergy, anastomotic stenosis, anastomotic leakage, abdominal bleeding, bowel obstruction, pulmonary infection, and abdominal infection occurred in any patients. Conclusions: FIGFI is helpful to judge the blood supply of intestinal segments and anastomotic stoma in total laparoscopic radical resection for right colon cancer quickly. It is a safe and feasible technique with satisfactory short-term effect.

Long noncoding RNA LINC01426 promotes glioma progression through PI3K/AKT signaling pathway and serves as a prognostic biomarker.

OBJECTIVE: Growing evidence indicated that long intergenic non-protein coding RNA 1426 (LINC01426) played important roles in tumor initiation and progression. However, little was known about the expression pattern and biological function of LINC01426 in glioma. Here, we aimed to determine its expression pattern, clinicopathological significance, and biological roles in glioma. PATIENTS AND METHODS: The Cancer Genome Atlas (TCGA) data was used to screen abnormally expressed lncRNAs in glioma. Reverse Transcription-Polymerase Chain Reaction (RT-PCR) was performed to detect the expression of LINC01426 in both glioma tissues and cell lines. Then, the associations between LINC01426 expression levels and various clinicopathologic characteristics and the clinical prognosis of patients with glioma were analyzed. The loss-of-function assay was performed to explore the effect of LINC01426 on glioma proliferation, metastasis, and apoptosis. Western blotting was performed to assess the protein expression levels. RESULTS: We identified a differentially expressed novel oncogenic lncRNA termed as LINC01426 by TCGA. Subsequent RT-PCT indicated that LINC01426 expression was significantly up-regulated in both glioma tissues and cell lines. Increased LINC01426 expression was negatively correlated with WHO grade and KPS score. Furthermore, LINC01426 could serve as an independent predictor for overall survival in glioma. In vitro assay revealed that knockdown of LINC01426 suppressed glioma cells proliferation, migration and invasion, and induced apoptosis. Mechanistic investigation showed that LINC01426 exhibited its tumor promoter role by modulating PI3K/Akt signaling pathway in glioma. CONCLUSIONS: The present study indicated that LINC01426 functioned as a tumor promoter and it might be a potential biomarker and therapeutic target in glioma.